MEDIAN Technologies will provide imaging services in an oncology phase III study led by a US specialty pharmaceutical company.
MEDIAN Technologies (ALMDT), a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials, today announced that it has been selected to provide imaging services in a phase III clinical trial. The study is sponsored by a US-based specialty pharmaceutical company. The anticipated amount for the project is €639K (eq. $ 870,400).
“We are proud of this new project award [*] and enthusiastic about working with both our CRO strategic partner and the specialty pharmaceutical company sponsor on this phase III study” said Fredrik Brag, Chairman and Chief Executive Officer of MEDIAN Technologies. “This award further reinforces the value of our alliance and strengthens our commercial positioning,” he added.
Within the framework of the study, imaging data will be acquired from approximately two dozen clinical sites, based in Europe and Asia, with anticipated total enrollment of 200 patients and a start date forecasted in Q2, 2014. MEDIAN will provide clinical site qualification and training, image data collection, quality control, centralized data storage, and Independent Central Review (ICR) services. ICR services will be performed by radiologists using MEDIAN’s Lesion Management Solutions (LMS) software. LMS is a comprehensive suite of software modules for the review of images and quantitative assessment of response to therapy in clinical trials. MEDIAN LMS provide sponsors with very accurate and reliable imaging data.
[*] A project award notifies a company that their solution has been selected for a given project. A binding contract is then signed within the 18 months following the award, upon confirmation of the upstream clinical results.